Pioneering a Future Without Crohn’s Disease

LinkedIn
Facebook

At INTERCEPT, we are transforming the landscape of Crohn’s disease research by shifting from reactive symptom management to proactive early detection and prevention. Our groundbreaking approach leverages biomarkers - measurable substances found in body fluids that can signal the presence of the earliest stages of the disease before it clinically manifests - to identify individuals at risk before symptoms develop, enabling timely and effective interventions that could stop the disease before it starts.

Objectives

Our mission is clear: make Crohn’s disease a manageable – or even preventable - condition by identifying and validating biomarkers that predict disease onset and progression.

To achieve this, we aim to:

Validate predictive biomarkers for Crohn’s disease.
Develop a blood risk score to identify high-risk individuals.
Establish early intervention pathways using clinically proven treatments.
Reduce the diagnostic burden and enhance patient care.
Build a collaborative network to accelerate biomarker validation.
Shift the approach from symptom management to proactive disease prevention.

By revolutionising Crohn’s disease detection, we are setting a new standard. One that could extend beyond Crohn’s to other chronic inflammatory diseases.

Our Approach

To bring this vision to life, INTERCEPT is launching a multinational study with partners in the United States, Europe and South Korea, combining cutting-edge science, advanced technologies and global expertise.

Our approach consists of three key elements:

  • Biomarker Validation & Risk Scoring
    • Recruiting 10,000 first-degree relatives of Crohn’s patients across seven European countries.
    • Developing a blood risk score to identify high-risk individuals before symptoms appear.
  • Preventative Intervention Trial
    • Selecting 80 high-risk participants for an innovative prevention trial.
    • Using proven medical treatments to intercept disease progression at the preclinical stage.
  • Global Collaboration & Infrastructure
    • Partnering with top universities, research centres and industry leaders across Europe, North America and South Korea.
    • Building a sustainable research framework to accelerate future biomarker-driven disease interception.

Impact & Vision

Our research is set to drive major advancements in the fight against Crohn’s disease and beyond.

Scientific breakthroughs
Accelerating biomarker validation and transforming early detection into clinical reality
Economic Impact
Positioning Europe as a global leader in early intervention research
Societal Change
Reducing the burden on patients and families by enabling early diagnosis and intervention
Clinical Innovation
Shifting from symptom management to a risk-based, proactive treatment approach

With INTERCEPT, our vision is clear: a future where Crohn’s Disease is not only manageable but potentially avoidable.

Together, we can change lives, redefine healthcare and pioneer a future without Crohn’s Disease.